The latest info for the MG community is right here!
How is the novel coronavirus pandemic impacting people with rare diseases and their families? Complete the 20-minute research survey from home or learn more at this link.
The Rare Diseases Clinical Research Network (RDCRN) is conducting this study. The network is funded by the National Institutes of Health. It includes 23 research teams working to advance diagnosis and treatment of groups of rare diseases. The Myasthenia Gravis Foundation of America and Conquer MG partners with RDCRN through its work with the Myasthenia Gravis Rare Disease Network (MGNet).
To view recorded presentations, resources and sponsor information, please complete a brief registration form and visit our virtual conference space here. Please see some helpful tips for navigating our virtual conference space here.
March 23, 2020
International MG/COVID Working Group*
International MG/COVID-19 Working Group1SaijuJacoba2SrikanthMuppidib2AmandaGuidoncJeffreyGuptilldMichaelHehireJames F.HowardJrfIsabelIllagRenatoMantegazzahHiroyukiMuraiiKimiakiUtsugisawajJohnVissingkHeinzWiendllRichard J.Nowakm2
Corona Virus Disease 2019 (COVID-19) is a new illness caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms are variable but typically include fever, cough, respiratory symptoms, diarrhea, reduction of smell and taste sensation. Severity ranges from mild to severe and the virus may lead to pneumonia, acute respiratory distress syndrome and death, in some patients. Nearly every country in the world has been affected by this virus and is currently defined as a pandemic, by the World Health Organization. There are no known proven therapies for treating this virus and no vaccine to prevent the infection at this time.
The full guidance is available here.
MGNet Webinar- "Myasthenia Gravis and the COVID-19 Epidemic: Things for you to know"
Presenters: Hana Axelrod, MD, MPH; Henry J. Kaminski, MD; Helen Girma, George Washington University Department of Neurology
We are pleased to share that the MGNet webinar, “MG and COVID-19: Things for you to Know” has been recorded and is available for viewing. We apologize for any technical difficulties in registering or participating in the webinar on March 18.
To view the recording of this webinar, please see here
MG Walks and COVID-19 (Coronavirus)
The health and safety of our participants, sponsors, volunteers and staff is our top concern. Currently, ALL spring walks from March 14-May 30 have been postponed until further notice. Additional details can also be found on our MG Walk website here.
We will look at potential dates for this fall and keep you updated as we learn more. If we are able to secure a fall date, then all donations will roll over to the new walk date.
**Any decisions made going forward will absolutely be dependent on where we are at with this global health crisis.
COVID-19 (Coronavirus)- General Information and Management
Due to the recent news regarding COVID-19 (coronavirus), we are providing some guidance around COVID-19, as well as reliable sources for information. See more information here.
MGFA announces 2020 research funding opportunities
We are pleased to announce the release of our Request for Applications for our High Impact Clinical Research and Scientific Pilot Projects on Myasthenia Gravis and Related Neuromuscular Junction Disorders.
We are also very pleased to announce our first targeted research opportunity to benefit the Seronegative MG community.
To learn about our research agenda and complete funding opportunities, see here.
For families with children that have myasthenia gravis, we have some exciting news to share. Thanks to a generous gift from an anonymous donor to the University of California, San Francisco, the first clinical Pediatric Myasthenia Gravis Consortium is now a reality. MGFA was honored to provide a grant to underwrite the costs for the September inaugural meeting of this exciting new project, and to participate on the advisory committee for the Consortium.
MGFA is proud to represent the MG Community as a member of MG Net, and has committed $250,000 of funding ($50,000 for each year) to support the project. This commitment from MGFA, as well as that of Illinois-based Conquer MG, was instrumental in demonstrating the support of the MG Community for the project—an essential component of the criteria for funding established by the NIH. Press release available here.
The National Institutes of Health (NIH) has awarded a research team at the George Washington University (GW) $7.8 million to establish a rare disease network for myasthenia gravis. The network, which will be part of 25 established NIH Rare Diseases Clinical Research Networks, will include basic and clinical investigators, patient advocacy groups and biotechnology and pharmaceutical companies working together to enhance therapeutic development for this rare disease. The team is led by former and current MGFA Medical and Scientific Advisory (MSAB) Chairs, Henry Kaminski, MD and Linda Kusner, PhD, and the steering committee members are all leaders of the MGFA MSAB as well.
The grant will fund research into the underlying pathophysiology of the disease, provide fellowships in MG for young investigators, and fund pilot grants. This funding will also ensure that the serum bank created by the MGFA’s transformative grant will continue.
Information on treatments, research and news that affects the MG community can change in an instant. We are your source for the latest, trusted information on MG. Add your email address to our mailing list to receive information on research, clinical trial opportunities, MG events and more direct to your inbox!
Magazines & Newsletters
- Focus on MG magazine: Our Focus on MG magazine is published twice a year. The magazine highlights MGFA programs and activities around the country. You can find useful information including MG community updates, practical advice on how to manage MG as a patient, caregiver, or friend and much more. Read the most recent issue.
- MG News: Our digital newsletter features the latest in MG research, clinical trial updates, advocacy and more. Our digital newsletter incorporates information from the public sector, private sector and from MGFA all in one place. Add your email address to our mailing list and receive information on research, clinical trial opportunities, MG events and more direct to your inbox!